The Metabolomics Market has witnessed significant growth due to an increasing need for accurate diagnosis of diseases, and the advanced technologies.
The Metabolomics Market is majorly segmented by product and service, application, indication, and region. Based on product and service, the market is segmented into metabolomics instruments and metabolomics bioinformatics tools & services.
Don’t miss out on business opportunities in Metabolomics Market.
The growing acceptance of metabolomics for personalized medicine, increasing pharmaceutical and biotech R&D expenditure, and continuous technological advancements are some of the factors driving market growth.
Metabolomics Market by Application:
the Metabolomics Market is segmented into biomarker discovery, drug discovery, nutrigenomics, toxicology testing, personalized medicine, functional genomics, and others.
Speak To Analyst: https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=900
Metabolomics Market biomarker Application;
this discovery segment accounted for the largest share of the global metabolomics market. This is mainly attributed to the improvement in both the efficiency and reliability of metabolic profiling of biomarkers and the accurate and clinically useful diagnostic capabilities of metabolic biomarkers for the management of diseases at the metabolic level. However, the personalized medicine segment is expected to register the highest CAGR during the forecast period due to collaborations between pharmaceutical companies and biotechnology firms for biomarker discovery and validation.
Major key players in Metabolomics Market;
Agilent Technologies, Inc. (U.S.), Thermo Fisher Scientific, Inc. (U.S.), Bruker Corporation (U.S.), Danaher Corporation (U.S.), Shimadzu Corporation (Japan), Metabolon Inc. (U.S.), LECO Corporation (U.S.), Biocrates Life Sciences AG (Austria), Human Metabolome Technologies, Inc. (Japan), and Waters Corporation (U.S.) are major key players.
